10-Q: Bristol Myers Squibb Reports Strong Q3 2026 Results

Bristol Myers Squibb announced a 7% increase in Q3 2026 revenues, driven by growth in its key portfolio and Eliquis, despite ongoing generic pressures on legacy products.

Summary

• Bristol Myers Squibb reported a 7% increase in total revenues for the third quarter of 2026, reaching $13.1 billion, and a 5% increase year-to-date to $37.5 billion.
• The Growth Portfolio saw a 12% increase in Q3 revenue to $7.7 billion, led by strong performance in Breyanzi, Opdualag, and Camzyos.
• Legacy Portfolio revenues remained relatively flat year-over-year in Q3 at $5.4 billion, with Eliquis showing significant growth (+25%) offsetting declines in Revlimid and Pomalyst due to generic competition.
• GAAP diluted EPS was $1.05 for Q3 2026, a slight decrease from $1.08 in Q3 2025, while non-GAAP diluted EPS was $1.35, down from $1.63.
• The company highlighted significant pipeline progress with multiple regulatory approvals and positive Phase III/II trial results across various therapeutic areas.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting solid revenue growth driven by key products, alongside significant pipeline advancements and strategic collaborations, though tempered by ongoing generic competition for legacy products.

Positives

• Total revenues increased by 7% to $13.1 billion in Q3 2026 and by 5% year-to-date to $37.5 billion.
• The Growth Portfolio revenue increased by 12% in Q3 2026 to $7.7 billion, driven by strong performance in Breyanzi (+46%), Opdualag (+23%), and Camzyos (+42%).
• Eliquis revenue increased by 25% in Q3 2026 to $4.7 billion, primarily due to higher average net selling prices in the U.S.
• Significant pipeline advancements include regulatory approvals for Zenbexus, Camzyos, Sotyktu, and Opdivo.
• Positive topline Phase III results were reported for the ALOFT-IPF study of admilparant and the ACTION-1 study of RYZ101.
• Strategic collaborations were strengthened with Hengrui for 13 early-stage assets and BioNTech for pumitamig.
• The company announced plans for new manufacturing facilities in Houston, Texas, and Whitestown, Indiana.

Negatives

• GAAP diluted EPS decreased to $1.05 in Q3 2026 from $1.08 in Q3 2025.
• Non-GAAP diluted EPS decreased to $1.35 in Q3 2026 from $1.63 in Q3 2025.
• Legacy Portfolio products like Revlimid (-47% in Q3), Pomalyst/Imnovid (-81% in Q3), Sprycel (-38% in Q3), and Abraxane (-13% in Q3) experienced significant revenue declines due to generic erosion.
• Acquired IPRD charges increased significantly to $1.6 billion in Q3 2026 from $633 million in Q3 2025, impacting earnings.
• Cost of products sold increased by 21% in Q3 2026, partly due to alliance profit sharing and a contract termination charge.

Risks

• Ongoing regulatory focus on prescription drugs may continue to pressure prices, reimbursement rates, and product accessibility.
• The Inflation Reduction Act (IRA) may lead to government-set prices for Eliquis (effective 2026) and Pomalyst (effective 2027), and potential future price negotiations for Orencia.
• Generic manufacturers are challenging patents for Eliquis in Europe and the U.S., potentially leading to earlier revenue erosion.
• Failure to successfully enforce patent rights could result in substantial decreases in product revenues from generic competition.
• The company faces ongoing litigation related to various products, including Camzyos, Eliquis, Opdivo, Plavix, Thalomid, Revlimid, and Pomalyst.
• Environmental remediation liabilities are estimated at $64 million as of September 30, 2026.

Future Outlook

The company continues to focus on discovering, developing, and delivering transformational medicines, driving commercial execution in key products, and strategically allocating capital for long-term growth. Future growth is expected from the Growth Portfolio and pipeline advancements, while managing the impact of generic erosion on legacy products and navigating evolving regulatory landscapes.

Management Comments

• Our principal strategy is to combine the resources, scale and capability of a large pharmaceutical company with the speed, agility and focus on innovation typically found in the biotech industry.
• Our priorities are to focus on transformational medicines where we have a competitive advantage, drive operational excellence and strategically allocate capital for long-term growth and shareholder returns.
• We continue to view business development as an important component of our strategy, focusing on opportunities where we can add strategic value and deliver returns.
• We remain committed to the strategic allocation of resources and investing in areas that maximize value and drive sustainable growth.

Industry Context

StockSavvy.ai notes that Bristol Myers Squibb's performance reflects broader industry trends, including strong growth in innovative therapies (oncology, immunology) and increasing pressure from generic competition on established blockbusters. The company's strategic focus on R&D and business development aligns with industry efforts to maintain growth pipelines amidst patent cliffs and evolving regulatory environments.

Comparison to Industry Standards

• The revenue growth of 7% in Q3 2026 is generally in line with or slightly above the average growth rates reported by large pharmaceutical companies with diversified portfolios, though some specialized biotech firms may show higher percentage growth from smaller bases.
• The significant increase in Acquired IPRD reflects aggressive investment in pipeline development and licensing, a common strategy among leading biopharmaceutical companies to secure future revenue streams.
• The company's R&D expenditure as a percentage of revenue (approximately 18% year-to-date) is consistent with industry benchmarks for major pharmaceutical firms heavily invested in innovation.
• The impact of generic erosion on legacy products like Revlimid and Pomalyst is a common challenge faced by the industry as patents expire, necessitating a strong pipeline of new products for sustained growth.

Legal Proceedings

• Patent infringement actions filed against generic manufacturers for Camzyos, Eliquis, and Opdivo.
• Ongoing litigation in Europe regarding Eliquis patents and Supplementary Protection Certificates (SPCs).
• Texas litigation concerning labeling, sales, and promotion of Plavix.
• Contingent Value Rights (CVR) litigation related to the Celgene acquisition, with a trial date set for January 2028.
• HRSA 340B litigation challenging the implementation of a cash rebate model, with the U.S. Court of Appeals affirming the District Court's judgment.
• Arkansas 340B litigation alleging violations of the Deceptive Trade Practices Act related to contract pharmacy policies.
• Antitrust class action lawsuits concerning Revlimid, Thalomid, and Pomalyst, with ongoing appeals and motions.

Stakeholder Impact

• Shareholders may see continued value creation from growth portfolio performance and pipeline advancements, but face near-term EPS pressure from IPRD and legacy product declines.
• Patients may benefit from new drug approvals and expanded indications for existing treatments.
• Payers and governments face ongoing scrutiny regarding drug pricing, with potential for negotiated prices impacting future revenues.
• Suppliers and business partners are involved in collaborations and licensing agreements, with financial terms detailed in the filing.

Next Steps

• Continue to advance late-stage R&D programs and pursue regulatory approvals for new indications and products.
• Execute on the strategic productivity initiative to achieve projected annual cost savings of $2.0 billion by the end of 2027.
• Invest in new manufacturing facilities to support future growth and domestic production.
• Defend intellectual property rights against patent infringement challenges.
• Monitor and adapt to evolving regulatory and pricing pressures, including the impact of the Inflation Reduction Act.

Key Dates

Recommendation

Bristol Myers Squibb demonstrates strong revenue growth driven by its innovative Growth Portfolio and key products like Eliquis. Significant pipeline progress and strategic collaborations offer long-term potential. However, the substantial impact of generic erosion on legacy products, increased R&D investments (Acquired IPRD), and ongoing legal challenges warrant a cautious 'hold' rating until the company demonstrates sustained EPS growth and navigates these headwinds more effectively.

Keywords

Bristol Myers Squibb, pharmaceuticals, oncology, hematology, immunology, cardiovascular, neuroscience, drug development